Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)

Partner Therapeutics’ zenocutuzumab (BIZENGRI®) received FDA approval for advanced unresectable/metastatic cholangiocarcinoma with an NRG1 gene fusion. In the eNRGy phase 2 cholangiocarcinoma cohort (n=22; 19 efficacy-evaluable), investigator-assessed ORR was 36.8% with median duration of response 7.4 months and median PFS 9.2 months, alongside a 57.9% clinical benefit rate. Safety was manageable with no patients discontinuing due to treatment-related adverse events; most treatment-related AEs were grade 1–2 (e.g., diarrhea 27.3%).

Analysis

This is more of a quality-and-durability confirmation than a step-change in economics. For MRUS, the market should focus less on the small addressable pool and more on what this says about the asset’s de-risking across tumor types: if a drug works in a molecularly defined orphan niche with manageable tolerability, it supports a higher probability-adjusted valuation for the broader pipeline. But the revenue math is still constrained by diagnosis friction, so the near-term P&L contribution is likely modest unless RNA-based testing becomes routine.

The second-order winner is not the drug itself but the testing funnel. The big hidden variable is conversion from DNA-only workflows to RNA-inclusive panels; that can create incremental volume for molecular diagnostics, pathology labs, and referral centers, while pressuring oncologists to abandon empiric salvage chemo in favor of molecular triage. For GMAB, I see little direct economic read-through unless investors choose to generalize this as validation of bispecific engineering capabilities; that is too soft to underwrite a stand-alone rerating.

Consensus may be overestimating commercial breadth and underestimating adoption bottlenecks. The catalyst path is: days = sentiment around “approved + published”; 1-3 months = prescription momentum, testing rates, and payer coverage; 6-18 months = whether this becomes a template for broader RNA-driven oncology screening. The thesis breaks if the label does not translate into measurable new starts or if RNA testing remains a niche add-on rather than standard workup.

Key Decisions for Investors

• MRUS: initiate a small long only on post-news weakness or structure as a 1-3 month long MRUS / short XBI pair to isolate idiosyncratic validation upside; target modest re-rating, not a blowout commercial outcome.
• GMAB: no fresh position; treat this as non-actionable for earnings until there is evidence of direct economic exposure or a disclosed royalty stream.
• Set a watch item on RNA-testing adoption and payer coverage over the next 1-2 quarters; if conversion rates do not improve, trim MRUS-related optimism because the commercial funnel is the real bottleneck.
• If MRUS rallies hard on headline enthusiasm, fade part of the move: the first-order approval is already in the price, while the durable upside depends on prescription data that will not be visible for several weeks.